Mary Jane  Lim-Fat

MD, MSc, FRCPC
Clinician Investigator, Associate Scientist
maryjane.limfat@sunnybrook.ca
Sunnybrook Health Sciences Centre
Phone: 416-480-6100 ext. 61960
Fax: 416-480-5753

Research Assistant:

Amanda Florez
Phone: 416-480-6100 Ext: 689893
Fax: 416-480-5054
Email: amanda.florez@sunnybrook.ca

My research interest is in studying the association between molecular and imaging predictors of clinical outcomes in glioma to elucidate patterns of response and resistance. I also have a particular research interest in young adult patients with CNS tumors, in an effort to find novel and more precise treatment strategies for this unique population.

Education

  • Master of Science, Epidemiology. Harvard Chan School of Public Health, Harvard University, Boston, MA, United States (2019-2021)
  • Neuro-Oncology Fellowship. MGH-DFCI-BWH Neuro-Oncology Fellowship Program, Dana Farber Harvard Cancer Center, Boston, MA, United States (2018-2020)
  • Adult Neurology Residency. Postgraduate Medical Education, Faculty of Medicine, University of Toronto, Toronto, ON, Canada (2012-2018)
  • Doctor of Medicine, University of Ottawa, Ottawa, ON, Canada (2008-2012)
  • Bachelor of Science (Honours), Life Science, Queen’s University, Kingston, ON, Canada (2004-2008)

Appointments and Affiliations

  • Associate scientist, Evaluative Clinical Sciences, Hurvitz Brain Sciences Program, Sunnybrook Research Institute
  • Lecturer, department of medicine, Division of Neurology, U of T
  • Co-lead, city-wide AYA CNS rounds

Research Foci

  • Adolescent and young adult CNS oncology
  • Clinical trials
  • Correlation of molecular and imaging biomarkers with clinical outcomes in brain tumors

Publications

Affiliated Labs & Programs

Selected Publications

  1. Lim-Fat MJ, Maralani PJ. Is there an optimal MRI surveillance schedule for patients with high grade glioma after standard of care therapy? Neuro Oncol. 2021 Mar 1:noab053. doi: 10.1093/neuonc/noab053. Epub ahead of print. PMID: 33674870.

  2. Lim-Fat MJ, Song KW, Iorgulescu JB, Andersen BM, Forst DA, Jordan JT, Gerstner ER, Reardon DA, Wen PY, Arrillaga-Romany I. Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol. 2021 Mar 1. doi: 10.1007/s11060-021-03719-5. Epub ahead of print. PMID: 33646525.

  3. Iorgulescu JB et al (including Lim-Fat MJ). Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res. 2021 Jan 1;27(1):276-287. doi: 10.1158/1078-0432.CCR-20-2291. Epub 2020 Nov 25. PMID: 33239433.

  4. Lim-Fat MJ, Nayak L, Meredith DM. Genomic Biomarker Assessment in Gliomas: Impacts of Molecular Testing on Clinical Practice and Trial Design. Surg Pathol Clin. 2020 Jun;13(2):209-215. doi: 10.1016/j.path.2020.02.003. Epub 2020 Apr 7. PMID: 32389262.

  5. Touat M et al (including Lim-Fat MJ). Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15. PMID: 32322066.